Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor–Associated Bleeding: A Retrospective Study
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Intensive Care Medicine"
DOI: 10.1177/0885066620916706
Abstract: Background: Although andexanet alfa was recently approved as a specific reversal agent for apixaban and rivaroxaban, some providers still elect to administer 4-factor prothrombin complex concentrate (4F-PCC) instead, due to concerns surrounding efficacy, thrombotic risk,… read more here.
Keywords: low versus; high dose; pcc; factor ... See more keywords